Innoviva, Inc. (INVA)
Automate Your Wheel Strategy on INVA
With Tiblio's Option Bot, you can configure your own wheel strategy including INVA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol INVA
- Rev/Share 5.9529
- Book/Share 10.316
- PB 1.9853
- Debt/Equity 0.6976
- CurrentRatio 2.4794
- ROIC 0.1128
- MktCap 1285636096.0
- FreeCF/Share 3.1254
- PFCF 6.5597
- PE -21.5036
- Debt/Assets 0.3597
- DivYield 0
- ROE -0.0894
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | INVA | Scotiabank | -- | Sector Outperform | -- | $55 | March 7, 2025 |
News
Innoviva to Participate in Upcoming Investor Conferences
Published: June 03, 2025 by: Business Wire
Sentiment: Neutral
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in June: Goldman Sachs 46th Annual Global Healthcare Conference 2025 Form.
Read More
Billionaire Healthcare Investor Alex Denner's Hedge Fund Has 75% of Its Assets in These 3 Stocks
Published: March 17, 2025 by: 24/7 Wall Street
Sentiment: Neutral
If you work in the biotech industry, you might know the name Alex Denner.
Read More
Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress
Published: February 26, 2025 by: Business Wire
Sentiment: Neutral
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the fourth quarter and full year ended December 31, 2024, and highlighted select corporate progress and achievements. Pavel Raifeld,.
Read More
About Innoviva, Inc. (INVA)
- IPO Date 2004-10-05
- Website https://www.inva.com
- Industry Biotechnology
- CEO Pavel Raifeld
- Employees 127